H.R. 5533 (109th): Biodefense and Pandemic Vaccine and Drug Development Act of 2006

Introduced:
Jun 06, 2006 (109th Congress, 2005–2006)
Status:
Died (Passed House)
Sponsor
Mike Rogers
Representative for Michigan's 8th congressional district
Party
Republican
Text
Read Text »
Last Updated
Nov 13, 2006
Length
30 pages
Related Bills
S. 2564 (Related)
Biodefense and Pandemic Vaccine and Drug Development Act of 2006

Referred to Committee
Last Action: Apr 06, 2006

S. 1873 (Related)
Biodefense and Pandemic Vaccine and Drug Development Act of 2005

Reported by Committee
Last Action: Oct 18, 2005

 
Status

This bill was introduced in a previous session of Congress and was passed by the House on September 26, 2006 but was never passed by the Senate.

Progress
Introduced Jun 06, 2006
Referred to Committee Jun 06, 2006
Reported by Committee Sep 20, 2006
Passed House Sep 26, 2006
 
Full Title

To prepare and strengthen the biodefenses of the United States against deliberate, accidental, and natural outbreaks of illness, and for other purposes.

Summary

No summaries available.

Cosponsors
11 cosponsors (6D, 5R) (show)
Committees

House Energy and Commerce

Health

Senate Health, Education, Labor, and Pensions

The committee chair determines whether a bill will move past the committee stage.

 
Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.

Widget

Get a bill status widget for your website »

Citation

Click a format for a citation suggestion:

Notes

H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.


9/26/2006--Passed House amended.
Biodefense and Pandemic Vaccine and Drug Development Act of 2006 - Amends the Public Health Service Act to establish the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services (HHS). Requires the Secretary of Health and Human Services to coordinate and oversee the acceleration of countermeasure and product advanced research and development.
Requires the Secretary to:
(1) facilitate and increase expeditious and direct communication with respect to such research and development;
(2) conduct ongoing searches for, and support calls for, potential qualified countermeasures and qualified pandemic or epidemic products;
(3) direct and coordinate such research and development activities of HHS;
(4) establish strategic initiatives to accelerate such research and development and innovation in priority unmet need areas; and
(5) connect interested persons with authorized offices or employees to advise such persons regarding relevant regulatory requirements related to qualified countermeasures or qualified pandemic or epidemic products.
Allows the Secretary to award contracts, grants, and cooperative agreements or enter into other transactions to promote:
(1) innovation in technologies that may assist such research and development;
(2) research on and development of research tools and other devices and technologies; and
(3) research to promote strategic initiatives, such as rapid diagnostics, broad spectrum antimicrobials, and vaccine manufacturing technologies.
Authorizes the Secretary to enter into other transactions for countermeasure and product advanced research and development.
Gives the Secretary expedited procurement authorities, the authority to expedite peer review, and the authority for personal services contracts.
Authorizes the Secretary to require that, as a condition of being awarded a contract, grant, cooperative agreement, or other transaction, a person make available to the Secretary relevant data related to or resulting from such research and development.
Exempts the Secretary's authority to enter into contracts from advertising and advance payment requirements.
Allows the Secretary to:
(1) use milestone-based awards and payments;
(2) make awards to and enter into transactions with highly qualified foreign national persons outside the United States under certain circumstances;
(3) establish one or more federally-funded research and development centers or university-affiliated research centers;
(4) give priority to the advanced research and development of qualified countermeasures and qualified pandemic or epidemic products that are likely to be safe and effective with respect to the emergency health security needs of children and other vulnerable populations;
(5) appoint highly qualified individuals to scientific or professional positions in BARDA without regard to federal provisions governing appointments in the competitive service;
(6) appoint special consultants; and
(7) accept voluntary and uncompensated services.
Requires the Secretary to withhold from disclosure under the Freedom of Information Act specific technical data or scientific information that is created or obtained during the countermeasure and product advanced research and development funded by the Secretary that reveals vulnerabilities of existing medical or public health defenses against biological, chemical, nuclear, or radiological threats.
Authorizes appropriations for FY2007-FY2008.
Requires the Secretary to establish the National Biodefense Science Board to provide expert advice and guidance to the Secretary on scientific, technical, and other matters of special interest to HHS regarding current and future chemical, biological, nuclear, and radiological agents.
Section 4 -
Includes within the definitions of "qualified countermeasure" and "security countermeasure" an agent to diagnose, mitigate, prevent, or treat harm from organisms that cause an infectious disease.
Deems as a qualified countermeasure without further administrative action any countermeasure for a biological agent if the Secretary determines that there is credible evidence that such agent has the potential to cause an epidemic or pandemic that may constitute a public health emergency.
Section 5 -
Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary to establish within the Food and Drug Administration (FDA) a team of experts on manufacturing and regulatory activities to provide technical assistance to the manufacturers of qualified countermeasures, security countermeasures, or vaccines if the Secretary determines that a shortage or potential shortage may occur.
(Sec, 6) Allows partial payment on a procurement contract for a security countermeasure for significant milestones or a payment to increase manufacturing capacity.
Allows procurement contracts to provide:
(1) for advance payments for milestones;
(2) that the vendor is the sole and exclusive supplier of the product to the government for a specified period if the vendor is able to satisfy the government's needs;
(3) that the vendor establish domestic manufacturing capacity of the product to ensure that additional production is available as necessary;
(4) dosing and administration requirements for countermeasures;
(5) the amount of funding that will be dedicated by the Secretary for countermeasure research and development; and
(6) specifications the countermeasure must meet to qualify for procurement under a contract.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.


No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 5533 (109th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus